Yapan Bio

Executive Summary

Yapan Bio, founded in 2020 and based in Hyderabad, India, is a specialty contract development and manufacturing organization (CDMO) providing end-to-end process development, scale-up, and GMP manufacturing for vaccines, recombinant biologics, gene therapy vectors, and monoclonal antibodies. With BSL-2+ facilities and integrated upstream/downstream capabilities, the company targets global biotech and biopharma partners seeking high-titer, stable, and compliant production for clinical studies. As a platform-stage private company employing 200-500 people, Yapan Bio leverages India's cost advantages and a skilled workforce to compete in the fast-growing CDMO market, particularly in biologics and advanced therapies. Yapan Bio's strong focus on quality and regulatory compliance positions it well to capture outsourcing demand from Western and Asian biopharma firms. The company's ability to handle both early-stage development and clinical-scale manufacturing offers a seamless partnership model. While still young, Yapan Bio is poised to benefit from the increasing complexity of biologics manufacturing and the global trend toward supply chain diversification. Key growth drivers include capacity expansions, strategic client wins, and potential WHO prequalification, which would open opportunities in emerging markets. The company's conviction score reflects its solid foundation and growth trajectory, though near-term catalysts are moderate.

Upcoming Catalysts (preview)

• Q2 2027Expansion of BSL-2+ manufacturing capacity70% success
• 2026Signing of a long-term CDMO agreement with a top-20 biopharma50% success
• Q4 2026Obtaining WHO prequalification for vaccine manufacturing60% success